FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964946950> ?p ?o ?g. }

• W1964946950 endingPage "538" @default.
• W1964946950 startingPage "532" @default.
• W1964946950 abstract "Objective: Angiogenesis, the development of new blood vessels, has become an area of increased interest for both scientific and clinical application purposes. Proangiogenic agents, such as vascular endothelial growth factor (VEGF) and naltrexone, have been shown to effectively induce new blood vessel growth. Other growth factors, such as the endogenous opioid growth factor (OGF; [Met5Klagsbrun M D'Amore P. Regulators of angiogenesis.Annu Rev Physiol. 1991; 53: 217-239Crossref PubMed Scopus (892) Google Scholar]-enkephalin) and retinoic acid, are inhibitors of angiogenesis. The differential effects on veins and arteries, however, by any vascular growth factor, have not previously been investigated. Methods: The chick chorioallantoic membrane (CAM) assay was used for the in vivo quantitation of angiogenesis. After 3 days of incubation, fertilized chick embryos were explanted, and a 3.2-mm methylcellulose disk containing either the known angiogenic stimulators VEGF (0.2 μg, 1.0 μg) or naltrexone (0.1 μg, 5.0 μg), or the angiogenic inhibitors OGF (1.0 μg, 5.0 μg) or retinoic acid (1.0 μg) was placed onto the CAM surface. An equal volume of distilled water served as a control. After 2 days of growth, the CAM arteries and veins were identified, and images were obtained with a digital camera. Quantitative analysis of angiogenesis was performed on a 100-mm2 area surrounding the applied disk, and the number and length of the veins and arteries were measured. Results: The angiogenic stimulators VEGF and naltrexone markedly increased both the total number and length of all blood vessels as compared with control values. The mean length of blood vessels decreased, suggesting the induction of new vessel growth. VEGF and naltrexone proportionately increased vein and arterial angiogenesis, maintaining artery/vein ratios for vessel number and length that were unchanged compared with controls. The angiogenic inhibitors, OGF and retinoic acid, notably decreased the total number and length of blood vessels in the CAM preparations. However, these compounds had a disproportionately greater inhibitory effect on arterial angiogenesis as reflected in decreased artery/vein ratios for vessel number and length. Conclusions: The angiogenic stimulators VEGF and naltrexone induce development of veins and arteries in a proportional manner. In contrast, the angiogenic inhibitors OGF and retinoic acid demonstrated a greater inhibitory effect on arterial as compared with venous angiogenesis. Such differential effects on angiogenesis may be important in both defining mechanisms of action and designing therapeutic interventions. (J Vasc Surg 2002;35:532-8.)" @default.
• W1964946950 created "2016-06-24" @default.
• W1964946950 creator A5022538892 @default.
• W1964946950 creator A5033014380 @default.
• W1964946950 creator A5059552811 @default.
• W1964946950 creator A5063088495 @default.
• W1964946950 creator A5065848191 @default.
• W1964946950 creator A5081137617 @default.
• W1964946950 date "2002-03-01" @default.
• W1964946950 modified "2023-10-11" @default.
• W1964946950 title "Differential effects of vascular growth factors on arterial and venous angiogenesis" @default.
• W1964946950 cites W1679229092 @default.
• W1964946950 cites W1838110840 @default.
• W1964946950 cites W1964417650 @default.
• W1964946950 cites W1980447845 @default.
• W1964946950 cites W1986559037 @default.
• W1964946950 cites W1993200993 @default.
• W1964946950 cites W2001879388 @default.
• W1964946950 cites W2002111141 @default.
• W1964946950 cites W2015253609 @default.
• W1964946950 cites W2015789556 @default.
• W1964946950 cites W2035595755 @default.
• W1964946950 cites W2039537741 @default.
• W1964946950 cites W2043508733 @default.
• W1964946950 cites W2046516822 @default.
• W1964946950 cites W2052398489 @default.
• W1964946950 cites W2058934794 @default.
• W1964946950 cites W2059711037 @default.
• W1964946950 cites W2065320333 @default.
• W1964946950 cites W2070395096 @default.
• W1964946950 cites W2094816691 @default.
• W1964946950 cites W2099154137 @default.
• W1964946950 cites W2107025256 @default.
• W1964946950 cites W2122034269 @default.
• W1964946950 cites W2134582008 @default.
• W1964946950 cites W2402977914 @default.
• W1964946950 cites W4239158126 @default.
• W1964946950 cites W4249388929 @default.
• W1964946950 doi "https://doi.org/10.1067/mva.2002.120042" @default.
• W1964946950 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11877704" @default.
• W1964946950 hasPublicationYear "2002" @default.
• W1964946950 type Work @default.
• W1964946950 sameAs 1964946950 @default.
• W1964946950 citedByCount "30" @default.
• W1964946950 countsByYear W19649469502012 @default.
• W1964946950 countsByYear W19649469502013 @default.
• W1964946950 countsByYear W19649469502015 @default.
• W1964946950 countsByYear W19649469502016 @default.
• W1964946950 countsByYear W19649469502019 @default.
• W1964946950 countsByYear W19649469502020 @default.
• W1964946950 countsByYear W19649469502021 @default.
• W1964946950 countsByYear W19649469502022 @default.
• W1964946950 countsByYear W19649469502023 @default.
• W1964946950 crossrefType "journal-article" @default.
• W1964946950 hasAuthorship W1964946950A5022538892 @default.
• W1964946950 hasAuthorship W1964946950A5033014380 @default.
• W1964946950 hasAuthorship W1964946950A5059552811 @default.
• W1964946950 hasAuthorship W1964946950A5063088495 @default.
• W1964946950 hasAuthorship W1964946950A5065848191 @default.
• W1964946950 hasAuthorship W1964946950A5081137617 @default.
• W1964946950 hasBestOaLocation W19649469501 @default.
• W1964946950 hasConcept C104317684 @default.
• W1964946950 hasConcept C126322002 @default.
• W1964946950 hasConcept C134018914 @default.
• W1964946950 hasConcept C142724271 @default.
• W1964946950 hasConcept C150903083 @default.
• W1964946950 hasConcept C167734588 @default.
• W1964946950 hasConcept C207001950 @default.
• W1964946950 hasConcept C2777025900 @default.
• W1964946950 hasConcept C2777663904 @default.
• W1964946950 hasConcept C2780394083 @default.
• W1964946950 hasConcept C2781121885 @default.
• W1964946950 hasConcept C55493867 @default.
• W1964946950 hasConcept C71924100 @default.
• W1964946950 hasConcept C86803240 @default.
• W1964946950 hasConcept C97230052 @default.
• W1964946950 hasConcept C98274493 @default.
• W1964946950 hasConceptScore W1964946950C104317684 @default.
• W1964946950 hasConceptScore W1964946950C126322002 @default.
• W1964946950 hasConceptScore W1964946950C134018914 @default.
• W1964946950 hasConceptScore W1964946950C142724271 @default.
• W1964946950 hasConceptScore W1964946950C150903083 @default.
• W1964946950 hasConceptScore W1964946950C167734588 @default.
• W1964946950 hasConceptScore W1964946950C207001950 @default.
• W1964946950 hasConceptScore W1964946950C2777025900 @default.
• W1964946950 hasConceptScore W1964946950C2777663904 @default.
• W1964946950 hasConceptScore W1964946950C2780394083 @default.
• W1964946950 hasConceptScore W1964946950C2781121885 @default.
• W1964946950 hasConceptScore W1964946950C55493867 @default.
• W1964946950 hasConceptScore W1964946950C71924100 @default.
• W1964946950 hasConceptScore W1964946950C86803240 @default.
• W1964946950 hasConceptScore W1964946950C97230052 @default.
• W1964946950 hasConceptScore W1964946950C98274493 @default.
• W1964946950 hasIssue "3" @default.
• W1964946950 hasLocation W19649469501 @default.
• W1964946950 hasLocation W19649469502 @default.
• W1964946950 hasOpenAccess W1964946950 @default.
• W1964946950 hasPrimaryLocation W19649469501 @default.

• next